Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia.
about
Phase I-II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukemia (CLL): effects on T cells and immune checkpoints.Safety and efficacy of Ofatumumab in chronic lymphocytic leukemia: a systematic review and meta-analysis.The use of ofatumumab in the treatment of B-cell malignancies.Ibrutinib versus previous standard of care: an adjusted comparison in patients with relapsed/refractory chronic lymphocytic leukaemiaAvailability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13.Strategies for clinical development of monoclonal antibodies beyond first-in-human trials: tested doses and rationale for dose selection.
P2860
Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Phase III, randomized study of ...... chronic lymphocytic leukemia.
@en
type
label
Phase III, randomized study of ...... chronic lymphocytic leukemia.
@en
prefLabel
Phase III, randomized study of ...... chronic lymphocytic leukemia.
@en
P2093
P2860
P50
P1433
P1476
Phase III, randomized study of ...... y chronic lymphocytic leukemia
@en
P2093
Anders Österborg
Andrey Zaritskey
Anna Schuh
Chai-Ni Chang
Grygoriy Rekhtman
Iryna Kryachok
Marco Montillo
Michael Steurer
Michele Gorczyca
P2860
P304
P356
10.3109/10428194.2015.1122783
P577
2016-01-19T00:00:00Z